Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 3, 2012

Funding for Diagnostic Biosensors and Rapid PharmacoDx Tests

  • The Qualcomm Foundation awarded Scripps Health a three-year, $3.75 million grant to be used by the Scripps Translational Science Institute (STSI) in its drive to develop new digital technologies for medicine. STSI is an NIH-supported consortium headed by Scripps Health in collaboration with The Scripps Research Institute and other scientific partners.

    The Qualcomm funds will more specifically be used support three programs: clinical trials of blood-carried wireless biosensor systems that can continually monitor for mutations, proteins, or antibody indicators of disease; the design of 20-minute pharmacogenomic diagnostic tests that can be carried out in pharmacies to determine an individual’s compatibility with specific drugs; and the development of apps and embedded sensors for tracking and predicting diseases and disorders including heart attacks, type 1 diabetes, and some cancers.

    “Scripps Health and our Scripps Translational Science Institute (STSI) partners are at the forefront of the development of wireless and genomic medicine,” states Chris Van Gorder, Scripps president and CEO. “The generous grant from the Qualcomm Foundation reinforces our efforts to translate innovative discoveries into transformative clinical therapies.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »